ArticleFrontiers in neurology2025
Association of plasma BMP6 levels with the rates of brain atrophy in older people without dementia.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone morphogenetic protein 6 (BMP6) has been implicated in the pathogenesis of Alzheimer's disease (AD), and its levels have been reported to be associated with cognitive performance. However, few studies have examined the association between plasma BMP6 levels and brain atrophy in older adults. Methods: A total of 340 older adults without dementia were included in the current study. Study participants had baseline plasma BMP6 data available and at least two structural MRI scans. Volumes of six brain regions were measured, including the hippocampus, entorhinal cortex, middle temporal gyrus, fusiform gyrus, ventricles, and whole brain. A series of linear mixed-effects models were built to examine the associations of plasma BMP6 levels with brain atrophy over time. Results: Our study revealed that higher plasma BMP6 levels were associated with a reduced rate of volume loss in the hippocampus, entorhinal cortex, middle temporal gyrus, and whole brain. However, there was no significant link between plasma BMP6 levels and changes in the volume of the fusiform gyrus or ventricles. Conclusion: Our results may provide novel insights into the mechanisms of neurodegeneration in AD, contributing to new avenues for timely intervention and potentially slowing disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.